Landmark CRISPR-Cas12a In-Vivo Gene Editing Halts Huntington’s Disease Progression in Phase II Trials

A Phase II clinical trial demonstrates that a novel in-vivo CRISPR-Cas12a gene editing therapy safely halts the progress...